Overview
Precision Instruments

CREATE MEDIC CO.,LTD.

Create Medic is a manufacturer and distributor of disposable catheters, tubes, and medical devices primarily made from silicone rubber. The company's core products include silicone catheters (notably Foley catheters and urological products) sold to hospitals and healthcare institutions. Its competitive strengths lie in specialized silicone material expertise and vertically integrated production across Japan, China, and Vietnam.

Market Cap
¥8.90B
US$56.8M
EV
¥3.26B
US$20.8M
Stock¥1,110▼-0.63%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
2.3
x
LTM EV/EBIT
4.1
x
LTM PER
15.9
x
LTM PBR
0.5
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-12.9%pt
100
Oct 24, 25 – Oct 23, 26StockTOPIX
MC → EV Bridge
8.90BUS$56.8MMarket Cap0.81BUS$5.18M+ Debt5.64BUS$36.0M− Cash0.82BUS$5.20M− Inv. Sec.3.26BUS$20.8MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
11.7US$74.6M'21/1212.3US$78.2M'22/1212.6US$80.3M'23/1213.0US$83.1M'24/1213.6US$86.8M'25/12
EBITDA 5Y (¥B)
1.33US$8.47M'21/121.34US$8.56M'22/121.39US$8.87M'23/121.33US$8.47M'24/121.58US$10.0M'25/12
Net Income 5Y (¥B)
0.66US$4.21M'21/120.46US$2.93M'22/120.15US$0.98M'23/120.84US$5.36M'24/120.71US$4.55M'25/12
Capital Structure
95%
EquityD/E 0.05xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
4.75US$30.3M0.80US$5.10M'21/124.85US$31.0M0.80US$5.10M'22/124.85US$30.9M0.80US$5.10M'23/126.94US$44.2M0.89US$5.69M'24/126.50US$41.5M0.81US$5.18M'25/12
Shareholders
Top 10 hold 47.5%
1
Tsuzuki Kikaku Co., Ltd.
14.40%
2
Hiromasa NAKAO
8.04%
3
Nakao Scholarship Foundation
7.48%
4
The Bank of Yokohama, Ltd.
5.26%
5
Masatsugu NAKAO
3.13%
6
Hikari Tsushin KK Investment Limited Partnership (General Partner: Hikari Tsushin, Inc.)
2.54%
7
Masataka KASAHARA
2.47%
8
CREATE MEDIC CO.,LTD. Employee Stock Ownership Association
1.69%
9
INTERACTIVE BROKERS LLC (Interactive Brokers Securities Co., Ltd.; Representative Director: Daniel KERRIGAN)
1.40%
10
Yoko AIKAWA
1.07%
Management
6 officers
Osamu IMAZAWA
Representative Director, President
Jan 2015 General Manager, Finance Department, Dance Knot Act Co., Ltd. Jun 2016 Joined the Company Oct 2016 General Manager, Corporate Planning Department Jan 2017 Manager, Corporate Planning Department Feb 2019 Supervisor, Create International Trade (Dalian) Co., Ltd. Mar 2019 Statutory Auditor, Vietnam Create Medic Co., Ltd. Mar 2020 General Manager, Administration Division Apr 2021 Executive Officer Mar 2022 Supervisor, Dalian Create Medical Products Co., Ltd. Mar 2023 Appointed Director Apr 2023 General Manager, Internal Audit Office Jan 2025 Representative Director, President (current)
1962-01-03
Yozo AKAOKA
Senior Managing Director (in charge of Development and Regulatory Affairs; in charge of Consolidated Group)
Aug 1985 Joined the Company Apr 1994 General Manager, Quality Assurance Office Mar 2002 Executive Officer Mar 2003 General Manager, Pharmaceutical Affairs and Legislation Division; Director, Dalian Create Medical Products Co., Ltd. Feb 2011 Director, Create International Trade (Dalian) Co., Ltd. Mar 2011 Appointed Director (current) Mar 2015 In charge of Medical Device Legislation Jun 2016 General Manager, Research and Development Center Apr 2017 General Manager, Development Division Jun 2017 Supervisor, Dalian Create Medical Products Co., Ltd. Mar 2020 Managing Executive Officer Apr 2021 In charge of Pharmaceuticals and Medical Devices Legislation; General Manager, Consolidated Management Division Mar 2022 Chairman, Create International Trade (Dalian) Co., Ltd. Mar 2023 Senior Executive Officer Jan 2025 In charge of Development Mar 2025 Appointed Senior Managing Director (current); in charge of Development and Regulatory Affairs (current); in charge of Consolidated Group (current)
1961-09-19
Katsuya AKIMOTO
Director (in charge of Domestic Sales; in charge of Exports)
Oct 1989 Joined the Company Sep 1999 Manager, Yokohama Sales Office, Clinie Business Division Jan 2007 Manager, Tokyo Sales Office, Medical Business Division Jul 2009 Metropolitan Area Supervisor, East Japan Sales Department, Medical Business Division Jan 2013 General Manager, Medical Business Management Division Apr 2013 Executive Officer Feb 2017 General Manager, Sales Division; General Manager, Medical Business Division Mar 2018 Appointed Director (current) Jan 2025 In charge of Domestic Sales (current); in charge of Exports (current)
1963-01-02
Atsushi HASHII
Director (Audit and Supervisory Committee Member)
Apr 1978 Joined The Bank of Yokohama, Ltd. Sep 2003 Joined the Company Jan 2004 Executive Officer Apr 2006 General Manager, Finance Department; Manager, General Planning Office Apr 2013 General Manager, Corporate Planning Department Mar 2014 Appointed Director; General Manager, General Management Division Apr 2016 Senior Executive Officer Jan 2017 General Manager, Administration Division Mar 2020 Appointed Director (Audit and Supervisory Committee Member) (current)
1955-01-29
Kazutoshi ISOGAI
Director (Audit and Supervisory Committee Member)
Apr 1979 Joined Asahi Accounting Firm (now Ernst & Young ShinNihon LLC) May 2002 Representative Partner, Asahi Accounting Firm Oct 2004 Head of Yokohama Office, Asahi Accounting Firm Jul 2018 Representative Director, Nihonbashi Accounting Co., Ltd. (current) Jun 2019 Outside Director, Alpha Co., Ltd. (current) Mar 2020 Appointed Director (Audit and Supervisory Committee Member) (current)
1955-12-21
Atsuko KUDO
Director (Audit and Supervisory Committee Member)
Sep 2003 Registered as attorney-at-law Oct 2003 Joined Kojima International Law Office Aug 2014 Enrolled in LLM Program in International Commercial and Maritime Law, Swansea University, UK Oct 2015 Trainee, JCS International Commercial Lawyers, London, UK Feb 2016 Trainee, Tilleke & Gibbins, Bangkok, Thailand Jan 2016 Completed LLM Program (Master of Laws) Apr 2018 Civil Mediation Commissioner, Tokyo Summary Court (current) Jun 2021 Auditor, Japan Fundraising Association, a Certified Specified Nonprofit Corporation (current) Aug 2021 Certified Business Innovation Support Provider (current) Mar 2023 Joined IPAX Law Office (current) Mar 2024 Appointed Director (Audit and Supervisory Committee Member) (current)
1963-08-13
Large Shareholding Reports
Yokohama Capital Co., Ltd.
2025-07-29
14.03%
Disclosures
No disclosures
Primary Source Filings
EDINET
2026-08-10
Semi-Annual Securities Report
Period: Jan 2026 – Dec 2026
TDnet
2026-08-05
Q2 Earnings Flash
FY ending Dec 2026
TDnet
2026-05-07
Q1 Earnings Flash
FY ending Dec 2026
EDINET
2026-03-26
Annual Securities Report
Period: Jan 2025 – Dec 2025
TDnet
2025-10-31
Q3 Earnings Flash
FY ending Dec 2025
EDINET
2025-08-08
Semi-Annual Securities Report
Period: Jan 2025 – Jun 2025
EDINET
2025-07-29
Large Shareholding Report
EDINETAmended
2025-07-14
Amended Securities Registration Statement
EDINETAmended
2025-07-08
Amended Securities Registration Statement
EDINET
2025-07-07
Securities Registration Statement
TDnet
2025-05-07
Q1 Earnings Flash
FY ending Dec 2025
EDINET
2025-03-28
Annual Securities Report
Period: Jan 2024 – Dec 2024
EDINET
2024-08-08
Semi-Annual Securities Report
Period: Jan 2024 – Jun 2024
EDINET
2024-05-10
Quarterly Securities Report
Period: Jan 2024 – Mar 2024
EDINET
2024-03-28
Annual Securities Report
Period: Jan 2023 – Dec 2023
EDINET
2023-11-08
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-08-08
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINETAmended
2023-08-08
Amended Quarterly Securities Report
Period: Jan 2023 – Mar 2023
EDINET
2023-05-11
Quarterly Securities Report
Period: Jan 2023 – Mar 2023
EDINET
2023-03-30
Annual Securities Report
Period: Jan 2022 – Dec 2022
EDINET
2022-11-08
Quarterly Securities Report
EDINET
2022-08-08
Quarterly Securities Report
EDINET
2022-05-11
Quarterly Securities Report
EDINET
2022-03-30
Annual Securities Report
EDINET
2021-11-05
Quarterly Securities Report
EDINET
2021-08-06
Quarterly Securities Report
EDINET
2021-05-11
Quarterly Securities Report
EDINET
2021-03-30
Annual Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →